that observational evidence shows a strong relation between n-3 PUFA and sudden death, but not between n-3 PUFA and non-fatal heart disease (Ascherio et al, 1995; Albert et al, 1998 Albert et al, , 2002 . This is confirmed by the outcome of clinical trials, the DART trial (Burr et al, 1989) showed an effect on fatal heart disease and the open-label GISSI trial (GISSIPrevenzione Investigators, 1999; Marchioli et al, 2002) suggests that n-3 PUFA specifically prevent sudden death. Sudden cardiac death is one of the most common and often the first manifestation of coronary heart disease. It is responsible for approximately 50% of all mortality from cardiovascular disease in the Western world (Zipes & Wellens, 1998) . The majority of sudden deaths are directly caused by acute ventricular arrhythmia (Huikuri et al, 2001 ).
An effect of n-3 PUFA on the incidence of fatal heart disease via arrhythmia seems more likely than an effect via other processes such as lowering of triglycerides (Marchioli et al, 2002) , prevention of atherosclerosis or thrombosis. Clinical trials show that only a few months of intake of n-3 PUFA are needed to decrease the incidence of cardiac events (Singh et al, 1997; Marchioli et al, 2002) , while effects on hard end points via atherosclerosis would be expected to take longer. Although n-3 PUFA do lower plasma triglyceride levels (Harris, 1997) , which would reduce atherosclerosis, angiographic trials do not consistently show an effect of n-3 PUFA on restenosis (Cairns et al, 1996; Eritsland et al, 1996; Johansen et al, 1999) . Significant effects of n-3 PUFA on bleeding time, haemostatic and fibrinolytic factors have only been observed in studies using doses of 2 g or more per day (Knapp, 1997; Kristensen et al, 2001) , while observational studies suggest beneficial effects already at doses of about 200 mg n-3 fatty acids per day (Kromhout et al, 1985; Siscovick et al, 1995; Albert et al, 1998 ). An effect of n-3 PUFA through reduced propensity for arrhythmia is also suggested by animal and in vitro experiments. Studies in dogs, monkeys and rats and in vitro studies have shown antiarrhythmic properties of n-3 PUFA (McLennan et al, 1988; Billman et al, 1994 Billman et al, , 1999 Leaf and Kang, 1996) . Intravenous infusion of fish oil fatty acids in dogs with ligated coronary arteries prevented ventricular arrhythmia after an exercise programme (Billman et al, 1994; Billman et al, 1997; Billman et al, 1999) . Dietary intake of fish oil prevented irreversible ventricular fibrillation after electrophysiological stimulation in rats and marmoset monkeys (McLennan, 1993; McLennan et al, 1988 McLennan et al, , 1993 . In cultured cardiomyocytes n-3 PUFA modulate the conductance of ion channels in the membrane and thereby prevent occurrence of arrhythmia .
Thus, observational as well as experimental evidence suggests that n-3 PUFA may prevent sudden death by suppressing life-threatening cardiac arrhythmia. Although this is an attractive and plausible hypothesis, it has not yet been proven. Therefore, we designed a randomised controlled clinical trial to directly test this hypothesis.
A trial investigating anti-arrhythmic effects would ideally require complete registration of all arrhythmic events. However, incidence of arrhythmias is difficult to observe and measure directly because arrhythmia duration is usually short and mostly happens outside the hospital. Fortunately, patients who have experienced life-threatening cardiac arrhythmia nowadays often receive an implantable cardioverter defibrillator (ICD). ICDs offer the opportunity to directly measure arrhythmic events. An ICD device is usually implanted under the skin of the chest. Its purpose is to monitor heart rate of the patient and to treat cardiac arrhythmia by shocking or pacing, if necessary. The ICD also records all arrhythmic events in a memory chip; the cardiologist can recover the data from outside the body by telemetric interrogation. Thus, the ICD enables continuous monitoring of events in nonhospitalised patients with a high risk of recurrent arrhythmias. This patient group therefore provides a very suitable population for testing a possible antiarrhythmic effect of n-3 PUFA.
This paper describes the rationale, design and methods of the Study on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA). It also reports results of a pilot study that preceded SOFA and discusses the problems that may be encountered in multicentre clinical trials of a food ingredient.
SOFA trial
Design SOFA is a randomised, placebo-controlled, double blind intervention study that is conducted in approximately 25 cardiology centres in Europe. SOFA plans to enrol 500 patients with an ICD. SOFA has a parallel design: patients randomly receive either 2 g of purified fish oilF containing approximately 900 mg of n-3 PUFAFor placebo oil (Loders Croklaan, Wormerveer, The Netherlands) for 1 year (Figure 1 ). SOFA is conducted according to the guidelines of Good Clinical Practice (GCP) for pharmaceutical trials.
Subjects

Sample size
We estimated the required sample size for SOFA using a power calculation based on an exponential distribution of survival rates (i.e. having no arrhythmic event) (Piantadosi, 1997) . We expect that approximately 35% of patients in the placebo group will experience at least one life-threaten- SOFA: randomised, placebo-controlled trial on n-3 fatty acids and cardiac arrhythmia IA Brouwer et al ing arrhythmia or death during the year of follow-up (Pacifico et al, 1999) ; thus, we applied an event-free survival of 65% for our power calculation. Based on data from earlier clinical trials and epidemiological studies, it can be postulated that n-3 PUFA would increase event-free survival from 65% in the placebo group to 78% (Albert et al, 1998; GISSI-Prevenzione Investigators, 1999 
Intervention
Treatment
The daily dose of 2 g (four capsules) of purified fish oil contains approximately 900 mg n-3 fatty acids (7450 mg eicosapentaenoic acid, 7350 mg docosahexaenoic acid and 780 mg other n-3 fatty acids). The source of the oil is anchovy. The dose is equivalent to, for example, 2-3 portions of salmon or mackerel per week. Placebo treatment consists of 2 g of high oleic acid sunflower oil. Oleic acid is chosen as a placebo because this mono-unsaturated n-9 fatty acids is already abundantly present in the diet. The additional intake of 2 g from placebo oil is small compared to the habitual daily dietary intake of oleic acid of approximately 30 g/day (Voedingscentrum, 1998) and is thus not expected to have any effects on the outcome of the study. Furthermore, in vitro experiments showed neither antiarrhythmic nor arrhythmic properties of oleic acid (Kang & Leaf, 1994) . Both the fish oil and the placebo oil contain 3000 ppm tocopherol as antioxidant.
Randomisation and blinding
Before the SOFA trial started, a randomisation list per clinical site was prepared. The randomisation list was prepared to randomise patients per clinical site in blocks of four units, each containing two placebo and two n-3 PUFA treatments. However, we later decided that patients should be stratified according to use of b-blockers, because use of b-blockers is considered a possible confounding factor. Therefore, patients using b-blockers as well as patients not using b-blockers are separately being randomised in blocks of two. A computer randomisation program randomly takes the first treatment of a block. The second patient in a block of two always receives the opposite treatment. Treatments (blinded medication numbers) are centrally assigned by a telephone allocation service. SOFA will be performed in a double blind manner. All possible measures are taken to blind the treatments for the participants as well as the investigators, technical staff for laboratory and data analysis throughout the trial. Fish oil and placebo capsules have identical appearance and the difference cannot be tasted if they are swallowed with cold liquid as instructed. The bottles containing the capsules (160 per bottle) are labelled with medication numbers that are unidentifiable for patients as well as investigators. Each patient receives a unique medication number.
Compliance
All patients report the intake of capsules in a diary, which is checked by research nurses every 4 months. We will obtain an impression of compliance by counting returned capsules and by inspecting the diaries. A more objective measure of compliance will be obtained by measuring the n-3 fatty acid composition in the serum cholesteryl esters, which directly reflects intake over the past weeks and months . The n-3 fatty acid composition in serum cholesteryl esters will be measured at baseline and at the end of the intervention period. Values at baseline will be also used to describe the n-3 fatty acid status of the study population and possible differences between intervention and placebo group at the start of the study. For these purposes, blood samples will be obtained after an overnight fast, centrifuged and stored at À801C until analysis of fatty acid composition in cholesterol esters by gas chromatography as described (Zock et al, 1997) .
Data collection
Patients visit their local clinic at baseline, and at 1, 4, 8 and 12 months follow-up. At each visit, the ICD is telemetrically interrogated and the data are stored on a computer disk. Additional information is recorded in the patient's case report form. Computer disks containing the ICD data covering the complete follow-up period are sent to the ICD Core Laboratory for central assessment (see under Practical Matters). At each visit a research nurse records results of clinical examinations (if performed), medication and adverse events in the patient's case report form.
Study outcome
Outcome measurements
The primary outcome of the trial is the occurrence of appropriate ICD intervention (shock or antitachycardia pacing) for spontaneous ventricular tachyarrhythmias, or all-cause mortality.
To explore whether n-3 fatty acids could affect cardiac outcomes other than spontaneous ventricular tachyarrhythmias, we formulated the following secondary outcomes: (1) all-cause mortality (separately from ventricular tachyarrhythmia), (2) cardiac mortality, (3) myocardial infarction, (4) all arrhythmic events as documented by the ICD Core laboratory, and (5) change in the prescription of antiarrhythmic drugs. Secondary outcome 4 comprises all events as documented by the ICD Core Laboratory. Thus, this includes not only all appropriate ICD intervention, but also all inappropriate shocks or antitachycardia pacing therapies, all aborted shocks or antitachycardia pacing therapies, shock or antitachycardia pacing therapy for ventricular arrhythmia Z140/min (430 ms), Z200/min (300 ms) or Z240/min (250 ms), or electric storms.
Data analysis
The primary analysis of the effect of n-3 PUFA will be performed on an intention-to-treat basis of all patients as randomised and will be based on time to first event. We will use time-to-event curves to describe the proportion of patients per treatment group who remained event-free during the 12-month intervention period. Time-to-event curves will be estimated by survival analysis. Differences in time-to-event between treatment groups will be statistically tested using log-rank tests.
Incidence densities and relative risks will also be calculated. Continuous variables will be analysed by use of a oneway analysis of variance or Wilcoxon's rank-sum test for unpaired samples (depending on the distribution of the variables). Categorical variables will be analysed by use of a w 2 or Fischer's exact tests. Multivariate analyses and corrections for multiple testing will be performed when appropriate.
In additional analyses, we will examine the efficacy of n-3 PUFA (ie excluding patients with insufficient compliance), and the effects of n-3 PUFA in particular subgroups of interest, for example patients with a prior myocardial infarction.
Organisation and quality assurance
The SOFA trial obeys all standards of Good Clinical Practice (GCP).
Committees
Several committees have been installed to manage and decide about different aspects of the trial. These include the Steering Committee, the Endpoint Adjudication Committee (EAC) and the Data Safety Monitoring Board. The final responsibility for the scientific conduct of the trial is with the Steering Committee. The Steering Committee consists of four cardiologists from the participating centres and three other scientists.
The Steering Committee has appointed four cardiologists as members of an Endpoint Adjudication Committee (EAC), which is responsible for the final judgement of the events.
The Data Safety Monitoring Board (DSMB) is installed to protect the interest and safety of the patients, while preserving the scientific integrity of the trial. It is responsible for review of the data and identification of any potential safety issues. The Data Safety Monitoring Board is independent from the trial organisation and comprises of one statistician and two cardiologists.
Resources
The Wageningen Centre for Food Sciences (WCFS) organises and funds SOFA. The Dutch Government established WCFS in 1997 as an independent research foundation. It consists of an alliance of Wageningen University and Research Centre (WUR), the TNO Institute for Nutrition and Food Research, and major Dutch food industries, with financial support by the Dutch government. The Dutch Government, Wageningen University and Research Centre and TNO together provide approximately 60% of the funding of WCFS. The remainder comes from eight major food industries in the Netherlands who pooled resources to enable long-term precompetitive research in the field of nutrition and food science. This collaborative approach has been designed to provide the necessary critical mass of multidisciplinary scientific expertise to achieve major advances in our understanding of food technology and nutrition and health. The fish oil preparation that is tested in the trial was bought on the open market, and the producer of this oil provides no funding for the trial, has no influence on the trial and no rights on intellectual property.
Clinical research organisation
The Wageningen Centre for Food Sciences is responsible for the central co-ordination of the SOFA trial, but it uses the expertise of the independent Clinical Research Organisation Cardialysis BV (Rotterdam) to organise the data management, the clinical monitoring and the ICD Core Laboratory (see under ICD Core Lab). Cardialysis obeys all standards of the European Union, the International Conference on Harmonisation (ICH), Good Clinical Practice (GCP), and the Food and Drug Administration (FDA).
ICD core laboratory
To reduce noise and thereby minimise the loss of power of the trial because of variation in outcome measurements, it is essential that all data on outcome are judged in a uniform way. Therefore, we set up a so-called 'ICD Core Lab' in which all events will be judged according to predefined criteria. This ICD Core Lab has been set up and developed specifically for the SOFA trial at Cardialysis (Rotterdam) and is up until now unique in Europe. Experienced Holter Core Lab technicians have been trained to assess ICD electrograms uniformly of all ICDs that are implanted in patients in SOFA. Reproducibility and validity studies are currently undertaken. The performance of the trained technicians will be monitored throughout the SOFA study.
The Investigators at the clinical sites store all output of the ICDs on computer disks. The Core Lab collects all computer disks. The technicians of the Core Lab judge the output by predefined criteria. Based on these criteria, the technicians record if and what type of events are stored by the ICD. The ICD Core Lab presents data sets of all events to the EAC. The EAC also receives data sets of all events reported by individual investigators. The EAC will also judge 10% of cases in which neither investigator nor the ICD Core Lab reports an event, but in which the ICD has stored any information. For those cases every 10th set of data is presented to the EAC.
The EAC judges all data presented to them. Two members of the EAC will judge each set of data. In case of agreement between two members, the judgement is final. In case of disagreement, a third member of the EAC decides about the final judgement. Members of the EAC will never judge data of patients from their own clinic. Both Core Lab personnel and members of the EAC only receive patient information that is needed to judge the data from the ICD, and in this way both Core Lab personnel and EAC members remain blinded to the treatments.
SOFA Pilot study
Before the actual SOFA trial started, we performed a pilot study according to a preliminary protocol of SOFA, but with an intervention time of 4 months instead of 12 months per patient. The pilot study was designed to judge the participation rate, to identify the main reasons for nonparticipation and to test the study procedures. It was performed in two hospitals in the Netherlands (Nieuwegein and Utrecht).
In the pilot study only patients who received an ICD for the first time were included. The inclusion and exclusion criteria for the pilot study, were similar to the ones used in the main trial except for the fish intake criterion and for the use of antiarrhythmic drugs. Patients were excluded if the cardiologist planned to continue the use of antiarrhythmic drugs after implantation of the ICD. However, use of betablockers and/or digitalis was allowed.
We have records of 30 patients who were screened for eligibility, but could not be included. In total, 17 patients participated in the pilot study.
Implications for the SOFA main study The pilot study showed that patients were very willing to participate. Patients who completed the intervention period reported intake of more than 90% of capsules in their patient passport. Before the pilot study, we developed a simple questionnaire on the frequency of fish consumption, to judge the usual fish intake of patients. Patients were interviewed using this 'fish consumption questionnaire' to assess their usual intake of total n-3 PUFA from fish, shellfish and fish oil capsules during the previous 3 months. We learned that the fish consumption questionnaire could be improved by adding a question on consumption of fish products in between meals. This modified questionnaire was validated against n-3 fatty acid status in cholesteryl esters in 97 apparently healthy subjects aged 50-70 years. This crosssectional validation study (results not shown) indicated that the questionnaire adequately ranks subjects according to their habitual intake of n-3 PUFA from fish products. The questionnaire is a suitable tool to assess and monitor n-3 PUFA intake from fish and shellfish in middle-aged adults. During the SOFA main study, we use the fish frequency questionnaire to exclude patients with a too high habitual fish intake, and to check whether patients retain their habitual intake of fish.
During the pilot study we excluded patients who consumed more than 4 g of n-3 fatty acids from fish per month as judged by the questionnaire. This was rather strict and seriously limited the number of patients that could be included. In the SOFA main study, we applied a somewhat more liberal criterion of fish intake: it was set at a maximum of 8 g per month, which is equivalent to 260 mg per day and to about 2-3 meals containing fatty fish per month. It is unlikely that this criterion will seriously compromise power, because the GISSI trial showed a large decrease in sudden death with supplemental intake of 900 mg n-3 PUFA over and above a habitual fish intake of at least once per week in more than 70% of the patients (Marchioli et al, 2002) .
Modifications to the protocol after the start of SOFA To keep a homogeneous as possible population, the initial SOFA protocol only allowed inclusion of patients who received an ICD for the first time, not of patients who already have an ICD. Furthermore, patients who continued the use of anti-arrhythmic drugs after implantation were excluded. Since the initial inclusion rate proved to be too low to complete the trial successfully the Steering Committee decided after inclusion of the first 30 patients to modify the inclusion and exclusion criteria. The main modifications made to the protocol were: inclusion of all patients with an earlier implanted ICD who experienced at least one confirmed arrhythmic event during the last year, and inclusion of patients who use antiarrhythmic drugs. The continued use of antiarrhythmic drugs after implantation was one of the main reasons for exclusion of patients, therefore we now include patients using antiarrhythmic drugs in the trial. By also including these patients and those with an earlier implanted ICD who recently experienced an arrhythmic event, the number of eligible patients will be enlarged enormously. Power of the trial will not be compromised much because only patients who experienced at least one arrhythmic event in the year before inclusion in the trial are included. These patients are at high risk of experiencing recurrent events. Furthermore, we plan to include 500 patients while according to our initial power calculation we will need 352 patients.
Crucial matters and problems
In the SOFA trial, we test the effectiveness of a regular food ingredient, n-3 fatty acids, in a randomised controlled clinical trial that is conducted according to the guidelines for GCP. Such trials, procedures and guidelines are common in pharmaceutical research, but are rare in nutrition and health research. In nutrition research clinical trials are often not feasible because of practical problems. However, this does not mean that evidence for health effects of foods should require lower standards than those for drugs. Nevertheless, organising a randomised clinical trial on food products brings along specific problems, some of which are depicted below.
SOFA is a multicentre study, which is conducted in several countries in Europe. This conveyed specific difficulties because we are obliged to follow the national regulations of each country, such as, for insurance of patients, ethical approval, and registration of a drug trial. For example, in Italy we faced the problem that a local Medical Ethical Committee (MEC) did not accept the insurance policy we effected although it obeyed all national regulations. Since insurance companies were not willing to provide a policy that fulfilled the guidelines of this local MEC, we were forced to drop this centre.
In the Netherlands, the guidelines for medical ethical approval of multicentre trials were renewed during the preparation phase of SOFA. The new procedures require approval from a central MEC as well as approval from all Dutch participating centres. The central MEC will suspend permission to start the trial until after approval from the other centres. These new procedures are complicated and time consuming and delayed the start of the participating centres in the Netherlands.
In Germany, the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) treated the SOFA trial as a drug trial and not as a trial on a food supplement. This in spite of the fact that fish oil capsules are freely available on the market and that they fall under the 'nutrition' law in Germany. The discussion with the BfArM whether the SOFA supplement was a food supplement or a drug and subsequently the registration of the trial at the BfArM took us about 8 months. A consequence was that a number of centres in Germany that were ready to start had to wait several months before they could actually start.
Timelines
The first patient entered SOFA in October 2001. We originally planned 6 months for all clinics to start the trial and an additional year to complete inclusion of patients. However, we experience several delays because of the above mentioned difficulties in organising a randomised clinical trial on food. Therefore, the planning of SOFA was adjusted: We now expect the last patient to enter the study in December 2003. Since we will stop intervention and follow-up of patients in August 2004, patients included after August 2003 will be followed for less than 1 year. This will not affect the main outcome of the trial as these patients will provide sufficient 'patient-months' to be useful for the 'time to first event' analysis. We aim to publish the results in 2005 (Figure 2 ).
Comments
A pertinent question is whether any effects of n-3 PUFA that may be found in this secondary prevention trial with patients could be generalised to primary preventive effects in the general population. Cardiac arrhythmias are the main direct cause of sudden death (Zipes & Wellens, 1998) . Patients with heart disease have an approximately 10 times SOFA: randomised, placebo-controlled trial on n-3 fatty acids and cardiac arrhythmia IA Brouwer et al higher risk of having a cardiac arrest than people in the general population have with no history of heart disease. Nevertheless, half of the people experiencing a cardiac arrest have no earlier diagnosed heart disease (Konings-Dalstra & Reitsma, 1999) and n-3 PUFA may provide primary protection in such cases. n-3 PUFA can be expected to be effective as soon as an arrhythmogenic substrate is present, thus as soon as, for example, ischemia or a myocardial infarction occur. This can be the case in patients with diagnosed cardiac disease but very well also in large parts of the general population. Several studies suggest that intake of n-3 fatty acids lowers the risk of heart disease and cardiac death, not only in patients (Burr et al, 1989; GISSI-Prevenzione Investigators, 1999) , but also in the general population (Albert et al, 1998 Hu et al, 2002) . Therefore, if SOFA shows a preventive effect of n-3 fatty acids on cardiac arrhythmia this would provide an additional argument to advise the general population to increase their fish intake. We chose to study cardiac arrhythmia in patients with an ICD because these patients are a very suitable population for directly testing effects on the incidence of arrhythmic events. A first reason is that the device can record all arrhythmias and recording of arrhythmic events would be virtually impossible in another population. A second reason is that patients with an ICD are at high risk of having recurrent arrhythmias. Thus, a similar trial in a lower risk population would not be feasible not only because arrhythmic events can not properly be measured, but mainly because it would require more than 10 000 patients to obtain a sufficient number of events and the consequent statistical power. Therefore, SOFA is an efficient approach to providing answer on the effectiveness of intake of n-3 fatty acids in the general population.
Food ingredients with health effects may have the advantage over drugs that they can be used for primary prevention in the general population without screening. Also, food ingredients generally do not have the adverse effects that most drugs have; the FDA stated that daily doses of EPA and DHA n-3 fatty acids of 3 g or lower are generally regarded as safe (GRAS) (62 Fed. Reg. 30,751, 1997) . Furthermore, n-3 PUFA can be implemented in regular foodstuff and habitual diet and in this way be supplied to a large part of the general population. If n-3 PUFA turn out to prevent cardiac arrhythmia, the food industry can produce functional foods containing additional n-3 PUFA that will be widely available for the general population. The call for a sound scientific basis for messages and claims about functional foods becomes stronger (Lawrence & Rayner, 1998; Katan, 1999) . Well-controlled trials like SOFA will become more and more important to substantiate claims on such functional foods. However, such trials are very expensive. In contrast to the pharmaceutical industry, which finances similar trials on drugs regularly, the food industry has lower profit margins and considerably less patent opportunities. This makes it less attractive and more difficult for the food industry to finance such trials.
If SOFA would show that n-3 PUFA indeed prevent cardiac arrhythmia, it can have a high impact on cardiovascular health on a population scale. Firstly, because cardiac arrhythmia are the most important cause of sudden cardiac death, which is responsible for approximately half of the cardiac death in the Western world. Secondly, because n-3 PUFA are a safe food ingredient that is easily implemented in the regular diets of the general population.
